![]() |
市場調查報告書
商品編碼
1473277
骨髓纖維化市場:KOL 洞察Myelofibrosis - KOL insight |
Jakafi/Jakavi 協會可能會透過新的聯合療法擴大規模,增加患者的處方並擴大治療選擇。最近批准的 Ojjaara/Omjara 為繼 Jakafi 後出現貧血的患者引入了一種有前途的選擇,並且根據 MOMENTUM 試驗的結果,預計將獲得顯著的採用。此外,perabresib 與 Jakafi/Jakavi 組合已成為一種突破性的非 JAK 抑制劑,預示著 MANIFEST-2 試驗後一種新的一線治療方法。
本報告研究了全球骨髓纖維化市場,並提供了市場概述,包括已上市的療法、管道趨勢和未來前景。
Explore the evolving landscape of myelofibrosis treatments in our latest insights report. Jakafi/Jakavi's relevance is poised to grow with new combination therapies, potentially increasing prescriptions and broadening patient treatment options. The recent approval of Ojjaara/Omjjara introduces a promising option for anaemic patients post-Jakafi, expected to see significant uptake based on MOMENTUM trial results. Additionally, Pelabresib is emerging as a groundbreaking non-JAK inhibitor in combination with Jakafi/Jakavi, heralding a new frontline treatment approach following the MANIFEST-2 trial. Stay ahead with these critical developments shaping the future of myelofibrosis care.